FMC Corp (FMC) Q3 2025 earnings review
Strategic Retreat: Asset Sales and Dividend Cuts Mark a Painful Reset
FMC delivered a chaotic Q3 report characterized by a massive strategic retreat. To address a deteriorating balance sheet (5.0x leverage) and negative cash flow, management slashed the dividend by >85% and booked a $569M net loss primarily due to writedowns on the India business now held for sale. While the 49% GAAP revenue decline is largely accounting noise from the India exit, the underlying business is also struggling: 'credit constraints' in Latin America caused a sales miss, and pricing power is eroding (-6% pricing impact). Management is now seeking covenant amendments, signaling financial stress remains acute despite the aggressive reset.
🐂 Bull Case
The 'Growth Portfolio' is working. Sales from new active ingredients nearly doubled YoY in Q3. Management maintains confidence in hitting $250M sales from these products in 2025, proving they can innovate away from generic pressure.
Despite top-line pressures, Adjusted EBITDA margin remained strong at ~25%. Management is aggressively cutting costs, targeting a complete manufacturing footprint overhaul by 2026 to compete with generic cost structures.
🐻 Bear Case
Leverage has ballooned to 5.0x Gross Debt/EBITDA, dangerously close to the 5.25x covenant limit. The company is forced to seek covenant amendments and cut the dividend to preserve cash, signaling distressed territory.
Free Cash Flow guidance was slashed from positive $200-$400M to negative $200M-$0. The culprit is 'delayed collections' in Latin America, raising fears about the quality of receivables and customer liquidity.
⚖️ Verdict: 🔴
Bearish. While the India exit and dividend cut are necessary bitter pills, the deterioration in free cash flow and the need for covenant relief suggest the turnaround is fragile. The core business faces pricing deflation that volume growth hasn't yet offset.
Key Themes
Liquidity Crisis & Dividend Slash
FMC unexpectedly cut its quarterly dividend from ~$0.58 to $0.08 per share. This move, designed to save ~$250M annually, was triggered by a collapse in operating cash flow ($184M outflow in Q3). With leverage at 5.0x and covenant waivers being sought, equity holders are effectively paying for the balance sheet repair.
Latin America Credit Freeze
A major operational red flag emerged in the key LATAM region. Revenue fell 8% YoY, but the bigger issue is 'credit constraints.' FMC effectively stopped shipping to certain customers in Brazil and Argentina due to liquidity risks. This implies that even if demand exists, FMC cannot monetize it without taking unacceptable credit risk.
India Divestiture & Accounting Noise
The 49% GAAP revenue drop is distorted by the India exit. FMC took back inventory and issued credits ($419M negative impact) to prepare the unit for sale. While this cleans the slate, the $227M impairment charge drove the massive quarterly loss. The business is marked down to $450M fair value, confirming significant value destruction in that region.
Innovation vs. Generics
The company is in a race against time. Sales of New Active Ingredients doubled YoY, a critical offset to the 'Core Portfolio' (Rynaxypyr) which is facing intense generic pricing pressure. The bull case rests entirely on these new products (fluindapyr, Isoflex) scaling faster than the legacy portfolio erodes.
Pricing Power Erosion
Pricing was a 6% headwind in Q3, driven by cost-plus adjustments on diamide contracts and generic competition. Management admits they must overhaul manufacturing just to compete on cost. This confirms that the era of premium pricing for their flagship molecules is ending faster than anticipated.
Other KPIs
Decelerating. While GAAP revenue collapsed, the 'real' continuing business revenue fell 4% YoY (organic). This metric strips out the noise of the India divestiture but still shows a business struggling for top-line traction despite new product launches.
Accelerating. Up 17% YoY despite the revenue decline. This is the one bright spot, driven by lower input costs and aggressive expense management. EBITDA margin expanded to ~25%, showing that while sales are hard to come by, the sales they do make are profitable.
Deteriorating significantly from 4.8x in Q2 and 3.7x in 24Q4. The covenant limit is 5.25x. This ratio is the primary constraint on the stock, forcing the dividend cut and effectively blocking any buybacks or M&A activity.
Guidance
Decelerating. Lowered from prior guidance of $4.08-$4.28B. The reduction reflects the exclusion of India but also the sales miss in Latin America due to credit tightening.
Reversing. A drastic cut from the previous guide of positive $200-$400M. This implies cash burn for the full year, a dangerous position for a leveraged company. Management cites delayed collections as the primary driver.
Accelerating. Implies ~2% YoY growth at the midpoint vs ex-India prior year. Management is banking on volume growth to finally turn positive, aided by the new product portfolio.
Key Questions
Covenant Amendment Terms
You are seeking covenant amendments with leverage at 5.0x. What concessions (interest rate hikes, collateral restrictions) are banks demanding in exchange for this relief?
Latin America Receivables
With credit constraints driving the sales miss and FCF burn, what is the risk of a major write-down on existing LATAM receivables in Q4?
Structural Margins
You are guiding for volume growth but pricing is down 6%. Can you maintain 25% EBITDA margins in 2026 if generic pricing pressure intensifies further?